Group 1 - The core point of the article is that Jia Bi You (688089.SH) experienced a significant stock price drop of 14.62%, reaching a low of 20.5 yuan, marking a nine-month low since April 10, 2025 [1] - The decline in stock price is attributed to quality issues with arachidonic acid oil (ARA) supplied to Nestlé, which has led to a recall of infant formula in multiple countries [1] - Jia Bi You has stated that they are in contact with testing agencies and regulatory bodies to conduct product testing, but results are not yet available, and no official announcement has been made regarding the findings [1]

Group 1 - Nestlé is recalling multiple batches of infant formula in 45 countries, including China, the UK, and Germany, due to quality issues with a supplier's raw materials [1][4][11] - The recall affects 71 batches of products under brands such as Wyeth, Lactogen, and NAN in mainland China [4] - The issue is linked to a bacterial toxin (cereulide) potentially found in arachidonic acid (ARA) oil used in some infant formulas [4][11] Group 2 - Jia Bi You, a biotechnology company from Wuhan, is identified as a potential supplier involved in the issue and is cooperating with regulatory authorities for product testing [1][5][8] - Following the news, Jia Bi You's stock price dropped over 14%, trading at 20.90 yuan per share, a decrease of 12.95% [1] - Jia Bi You reported a 25% year-on-year revenue increase to 556 million yuan, with ARA products contributing 70% of its revenue [9] Group 3 - Other dairy companies, including Danone, Junlebao, and Arla, have confirmed they do not use raw materials from the implicated supplier and assured consumers of product safety [3][10] - Danone stated that all its imported infant formula products are produced to high standards and do not involve the affected supplier [10] - Arla conducted a thorough review of its products and confirmed that its ARA oil suppliers are not linked to the recall [10] Group 4 - Nestlé emphasized that the recalled batches represent less than 0.5% of its annual sales, indicating a limited financial impact from the recall [11] - The company is working closely with the implicated supplier, which is conducting a comprehensive root cause analysis [11] - No disease cases related to the recalled products have been confirmed so far [11]

Core Viewpoint - The Nestlé infant formula recall has led to significant market disruptions, affecting not only Nestlé but also other brands and suppliers in the industry, with potential long-term impacts on consumer trust and brand reputation [2][3][4]. Group 1: Recall Details - On January 6, Nestlé announced a recall of certain batches of infant formula across 31 countries due to quality issues with ARA oil, which may contain Bacillus cereus, a bacteria that can cause foodborne illness [3][4]. - The recall involves 71 batches of products from Nestlé and Wyeth, covering at least 15 series of infant formula and one series of children's growth formula [3][4]. - Nestlé stated that the affected batches represent less than 0.5% of its annual sales, indicating a limited financial impact on the company [4]. Group 2: Market Reactions - Following the recall announcement, there has been a surge in irrational returns from customers, with some retailers reporting significant increases in return requests, regardless of whether the products were part of the affected batches [2][5]. - Competitors have begun to capitalize on the situation, with some brands actively promoting their products as safe alternatives [5]. - The recall has raised concerns about consumer sensitivity to quality issues in infant formula, which could lead to a more significant impact on Nestlé's market share in China compared to other regions [5]. Group 3: Impact on Suppliers - The recall has also affected multiple suppliers, with companies like Danone and HiPP clarifying that they do not use the implicated ARA supplier [7][8]. - DSM-Firmenich, the largest ARA supplier, confirmed that the problematic ARA was not produced by them, leading to increased demand for their ARA products [9][12]. - The A-share listed company, Jia Bi You, has been identified as a potential supplier of the problematic ARA, with its stock price dropping over 10% following the news [2][12][13]. Group 4: Financial Implications - In 2024, despite gaining market share, Nestlé's infant nutrition business in Greater China is projected to show negative growth, with an organic growth rate of -6.1% reported for the first three quarters of 2025 [6]. - Market data indicates that Nestlé and Wyeth hold a combined market share of approximately 9.3% in China's infant formula market, trailing behind competitors like Feihe and Danone [6].

Core Viewpoint - The Nestlé infant formula recall has led to significant market disruptions, affecting not only Nestlé but also other brands and suppliers in the industry, with potential long-term impacts on consumer trust and sales performance [1][2][3]. Group 1: Recall Details - On January 6, Nestlé announced a recall of certain batches of infant formula across 31 countries due to quality issues with ARA (arachidonic acid) oil, which may contain harmful bacteria [2][3]. - The recall involves 71 batches of products from Nestlé and Wyeth, affecting at least 15 series of infant formula and one series of children's growth formula [3][4]. - Nestlé's assessment indicates that the affected batches represent less than 0.5% of the group's annual sales, suggesting limited financial impact on the company [4]. Group 2: Market Reactions - Following the recall announcement, there has been a surge in irrational returns from customers, with some retailers reporting significant increases in return requests, regardless of whether the products were part of the affected batches [1][5]. - The recall has led to a decline in confidence among distributors, particularly affecting Nestlé's high-end infant formula "Platinum Enfamil," which may face severe market challenges [1][5]. Group 3: Impact on Competitors and Suppliers - Other infant formula brands and suppliers, including Danone and HiPP, have clarified that they do not use the implicated ARA supplier, distancing themselves from the recall [8][9]. - The largest ARA supplier, DSM-Firmenich, confirmed that the problematic ARA was not produced by them and noted an increase in market demand for their ARA products due to the recall [10][18]. - The A-share listed company, Jia Bi You Biotechnology, is under scrutiny as it is suspected to be the supplier of the problematic ARA, leading to a significant drop in its stock price [1][17]. Group 4: Financial Performance and Market Share - In 2024, despite a market share increase in the infant nutrition sector, Nestlé's overall performance in the Greater China region is projected to show negative growth, with a reported organic growth rate of -6.1% for the first three quarters of 2025 [7]. - Market data indicates that Nestlé and Wyeth hold approximately 4.9% and 4.4% market shares, respectively, in the Chinese infant formula market, trailing behind competitors like Feihe and Danone [7].

Core Viewpoint - The incident involving the recall of infant formula by Nestlé due to quality risks associated with ARA supplied by Jia Bi You has led to a significant drop in Jia Bi You's stock price, highlighting potential risks in the supply chain and consumer confidence in the company [2]. Group 1: Incident Overview - Nestlé announced a global preventive recall of certain batches of infant formula in 31 countries due to quality risks linked to ARA supplied by Jia Bi You [2]. - The recall affects four brands in the Chinese market, totaling 30 batches, while other Nestlé products remain unaffected [2]. - The substance Cereulide, potentially harmful and produced by Bacillus cereus, was detected in the ARA oil provided by the supplier [2]. Group 2: Company Impact - Jia Bi You's stock price fell over 13% following the announcement of the recall [2]. - The company's ARA business generated revenue of 390 million yuan in 2024, marking a year-on-year increase of 29.2%, indicating its significance to the company's core operations [3]. - Jia Bi You has stated that its ARA products have passed certifications in Europe and the U.S. and are supplied to various dairy companies [3]. Group 3: Industry Response - Other dairy companies are monitoring the situation closely, with some clarifying that they do not use the implicated ARA from Jia Bi You [3][4]. - The supply chain for infant formula ingredients is generally concentrated, which may affect the industry dynamics depending on the outcome of the investigation [4].

Core Viewpoint - The article discusses the recent recall of infant formula by Nestlé due to potential quality risks associated with ARA supplied by Jia Bi You Biotechnology, leading to a significant drop in Jia Bi You's stock price by over 13% [3]. Group 1: Incident Overview - Nestlé announced a global recall of certain batches of infant formula in 31 countries due to the detection of Cereulide in ARA oil, which is linked to Bacillus cereus and can cause foodborne illness [3]. - The recall affects four brands in the Chinese market, totaling 30 batches, while other Nestlé products remain unaffected [3]. Group 2: Company Impact - Jia Bi You's ARA business generated revenue of 390 million yuan in 2024, marking a 29.2% year-on-year increase, making it a core part of the company's operations [5]. - Following the incident, Jia Bi You has sent its products for testing and will release results once available [5]. Group 3: Industry Response - Other dairy companies have distanced themselves from the incident, stating they do not use the implicated ARA from Jia Bi You [5]. - The ARA market is concentrated among a few suppliers, and the situation is being closely monitored by industry analysts [5].

Group 1 - Jia Bi You Biotechnology (Wuhan) Co., Ltd. (stock code 688089.SH) is involved in Nestlé's global preventive recall of infant formula due to quality risks associated with ARA supplied by the company, leading to a stock price drop of over 13% [2] - Nestlé announced a recall of certain batches of infant formula in 31 countries, including China, due to the detection of Cereulide in ARA oil, which is produced by Bacillus cereus and can cause foodborne illness [2] - The affected products in China include four brands: Lidojing, Platinum Neng'en, Shuyi Neng'en, and Wyeth's Shaner Children's Growth Formula, totaling 30 batches, while other Nestlé products are not impacted by the recall [2] Group 2 - ARA (Arachidonic Acid) is a widely used Omega-6 polyunsaturated fatty acid in infant formula and dietary supplements, drawing significant consumer attention due to the incident [3] - Major ARA producers include DSM, Jia Bi You, and Runke Biotechnology, but Nestlé did not disclose the specific supplier involved in the issue [3] - Jia Bi You reported an ARA business revenue of 390 million yuan for 2024, a year-on-year increase of 29.2%, indicating that ARA is a core business for the company [3]

Core Viewpoint - The incident involving the recall of infant formula by Nestlé due to quality concerns related to ARA supplied by Jia Bi You has led to a significant drop in the company's stock price, highlighting potential risks in the supply chain and consumer confidence [1][2]. Group 1: Company Impact - Jia Bi You Biotechnology (Wuhan) Co., Ltd. has seen its stock price drop over 13% following the announcement of the recall by Nestlé [1]. - The company has stated that it has sent its products for testing and will release an announcement once the results are available [2]. - Jia Bi You's ARA business revenue for 2024 is projected to be 390 million yuan, reflecting a year-on-year growth of 29.2%, indicating that ARA is a core business for the company [2]. Group 2: Industry Context - The recall involves ARA, a widely used Omega-6 fatty acid in infant formula, which has raised consumer concerns in China [2]. - Major producers of ARA include companies like DSM, Jia Bi You, and Runke Biotechnology, with Nestlé not disclosing the specific supplier involved in the issue [2]. - Some dairy companies have distanced themselves from the incident, stating they do not use the implicated ARA raw materials, while others are monitoring the situation closely [2][3].

记者丨 贺泓源 实习生韦怡琦 编辑丨高梦阳 雀巢多国召回婴儿配方奶粉事件有了进展。 2026年1月7日，雀巢的花生四烯酸油（ARA）产品供应商嘉必优向21世纪经济报道记者透 露， 相关原料检测中，尚未出结果。"我们正联系相关的检测机构，包括监管部门，来做产品 检测，现在尚未出结果，所以暂时并未公告。 结果出来以后我们会及时进行公告。"嘉必优证 券部相关负责人称。 作为对比，同天，帝斯曼-芬美意发布声明强调，涉事问题ARA原料并非由帝斯曼-芬美意供 应。"因以上事件影响，帝斯曼-芬美意ARA原料需求激增，我们将全力协调产能，满足市场需 求。"该公司表示。 此次雀巢多国召回婴儿配方奶粉，正是受供应商提供的ARA原料存在质量问题影响。 回到嘉必优，该公司正在ARA市场狂奔。 前三季度， 嘉必优营收同比增长10.56%至4.28亿元 ；归母净利润同比增长54.18%至1.29亿 元。嘉必优在财报中提到， 其目前是国内最大ARA产品供应商， 也是国际ARA产品竞争最重 要的参与者。 "随着帝斯曼全球 ARA 专利陆续到期，公司大力拓展国际客户开发，积极提高自身境外销售 能力，完善国际化运营团队和客户服务体系，推动公司产 ...

21独家｜嘉必优回应雀巢奶粉召回：相关原料检测中，尚未出结果 21世纪经济报道记者贺泓源、实习生韦怡琦 雀巢多国召回婴儿配方奶粉事件有了进展。 2026年1月7日，雀巢的花生四烯酸油(ARA)产品供应商嘉必优向21世纪经济报道记者透露，相关原料检测中，尚未出结果。"我们正联系相关的检测机构， 包括监管部门，来做产品检测，现在尚未出结果，所以暂时并未公告。结果出来以后我们会及时进行公告。"嘉必优证券部相关负责人称。 作为对比，同天，帝斯曼-芬美意发布声明强调，涉事问题ARA原料并非由帝斯曼-芬美意供应。"因以上事件影响，帝斯曼-芬美意ARA原料需求激增，我们 将全力协调产能，满足市场需求。"该公司表示。 1月7日，雀巢中国向21世纪经济报道记者透露，雀巢欧洲部分市场对婴幼儿配方奶粉产品启动了预防性回收措施，雀巢中国对此高度重视，中国市场少数产 品可能受到影响。作为预防性举措，雀巢中国已经对部分特定批次的婴幼儿配方奶粉进行了回收。"截至目前，我们尚未收到与相关产品有关的任何不适报 告。所有在中国大陆市场注册并销售的雀巢特殊医学用途婴儿配方食品、超启能恩、启赋、S26铂臻等不受影响。"雀巢中国称。 此次雀巢多国召回 ...